Benchling has seen its business grow at a healthy lick since it launched in 2012 with a mission to improve the efficiency of the biopharma R&D process, but it looks li
It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better outcome at its second attempt.